DevCurationThe Premier Voice of the Entire Tech Ecosystem
Home
Where the Money Moved
News
Events
Investor Spotlight
Company Spotlight
Frameworks
DevCuration
Home
Where the Money Moved
News
Events
Investor Spotlight
Company Spotlight
Frameworks
DevCuration
Latest
Corma Raises $125M Series A for Defensive CybersecurityCorma Raises $125M Series A for Defensive Cybersecurity|Betterness Raises $1M to Expand Miami Wellness Networks|Focus Financial Partners Agrees to Apollo Strategic Investment|Knit Health Raises $35M Series A for Clinical AI Deployment|COUNT Raises $6.5M Seed to Expand AI Accounting Platform|Numa Raises $45M Series C for Dealership AI Expansion|Remedy Robotics Raises $62M Series B for N1 Clinical Trials|Alecto Raises $20M Seed for AI-Native Consumer Law|Verlo Raises C$4.5M Seed for Wealth Management AI|Cohere Acquires cubic to Build Its Secure Coding Business|Corma Raises $125M Series A for Defensive CybersecurityCorma Raises $125M Series A for Defensive Cybersecurity|Betterness Raises $1M to Expand Miami Wellness Networks|Focus Financial Partners Agrees to Apollo Strategic Investment|Knit Health Raises $35M Series A for Clinical AI Deployment|COUNT Raises $6.5M Seed to Expand AI Accounting Platform|Numa Raises $45M Series C for Dealership AI Expansion|Remedy Robotics Raises $62M Series B for N1 Clinical Trials|Alecto Raises $20M Seed for AI-Native Consumer Law|Verlo Raises C$4.5M Seed for Wealth Management AI|Cohere Acquires cubic to Build Its Secure Coding Business
DevCuration

The premier voice of the tech ecosystem, from ideation to enterprise.

Explore

  • Where the Money Moved
  • Events
  • Articles & Analysis

Spotlights

  • Investor Spotlight
  • Company Spotlight
  • Frameworks

Company

  • About Us
  • Privacy Policy
  • Terms of Service
© 2026 DevCuration. All rights reserved.
TwitterLinkedIn
Logos provided by Logo.dev
Back to articles
November 16, 2026
•Jesse LandryJesse Landry

Remedy Robotics Raises $62M Series B for N1 Clinical Trials

A specialized team stayed beside the patient when Remedy Robotics helped a Toronto surgeon operate from another hospital. That detail gives the San Francisco company's latest financing its practical stakes: extending a physician's reach also means making the hospital at the other end ready to receive it.

Remedy announced a $62M Series B on November 16, 2026, led by DCVC. The capital will support planned pivotal clinical trials with the University of California, work toward FDA approval for neurovascular intervention and prototype deployments of its N1 robotic platform. CEO and co-founder David Bell and CTO and co-founder Jake Sganga are pursuing a care model in which specialist expertise can reach beyond the hospital that employs it.

N1 remains investigational, with safety and effectiveness for clinical use yet to be established. Its earlier remote human procedures were diagnostic angiograms, an important distinction as Remedy works toward more complex treatment and develops autonomous capabilities. The investment finances a clinical development program whose eventual value will depend on the people and institutions around the device as well as the machinery itself.

What Remedy's Series B Will Finance

New investors UC Investments, Skip Capital and Hostplus joined the round. Existing backers Build Collective by Tony Fadell, Blackbird, Divergent Capital and KdT Ventures also participated, bringing a mix of venture investors and institutional capital into the next phase. Remedy has not disclosed a valuation in the announcement.

The University of California relationship has particular weight. Its investment office is a new financial backer, while its clinical network is the planned setting for pivotal trials. Sganga says Remedy has worked with UC clinical experts since 2021. Those relationships give the company a route into a demanding clinical environment; they should be understood separately from regulatory authorization or proof of patient benefit.

Remedy also plans prototype deployments through partners including SVIN Mission Thrombectomy and the Australian Stroke Alliance. The company reports working with more than 100 hospitals worldwide, a measure of its relationships rather than a disclosed commercial installed base. Neither pricing nor revenue was provided, so the size of that network cannot be translated into sales.

DCVC's earlier account described $35M in previously raised seed and Series A financing. The new round continues a development effort already spanning robotics, imaging and clinical collaboration. For a prospective hospital buyer, that combination raises a practical question: how much of the surrounding workflow can arrive with the system, and how much must the hospital build around it?

What the Toronto Procedures Actually Established

In Unity Health Toronto's account, Vitor Mendes Pereira performed diagnostic angiograms on patients at St. Michael's Hospital while controlling the robot from St. Joseph's Health Centre. A specialized clinical team remained with the patients. The late-August 2025 cases used the fibre connection linking the hospital network, following extensive testing and simulation.

The initial cases assessed blood vessels through angiographic imaging. Unity Health explicitly distinguishes that work from subsequent remote treatments that would navigate devices into the brain's blood vessels. Keeping the distinction visible gives readers a more useful development record than treating every procedure as the same achievement.

The bedside team's continuing role also explains why the operating model matters. Remote control moves an operator's location; it leaves a patient whose care still depends on local preparation, support and coordination. A hospital considering this approach would have to understand that division of responsibility before it could judge what new service the robot might make possible.

For Remedy, the planned UC trials bring that wider assignment into sharper focus. Clinical development has to connect the system's intended use with a defined body of evidence. The funding announcement does not provide trial enrollment, endpoints or a start date, leaving those details open as the program advances. Operators can follow the development without mistaking an earlier diagnostic milestone for an already available stroke-treatment service.

Why Imaging and Connectivity Belong in the Product

Remedy's technology description puts imaging, tool control and remote communications inside the same platform. It describes automated segmentation, patient-specific preoperative simulation and real-time registration of 3D images with 2D procedural views. The aim is to help the operator relate a device's movement to the patient's anatomy while working through the available images.

The remote package includes connectivity management, audio and video. Those functions may attract less attention than a robotic catheter, but they belong to the same care proposition: a physician at a distance needs to understand and coordinate what is happening at the patient. Buying more sophisticated movement would solve only part of that assignment.

Remedy also describes the platform as a foundation for supervised autonomy. That is a development direction, alongside the current investigational system and planned clinical work. The company has not announced that fully autonomous cardiovascular treatment is available for routine use, and its present regulatory status needs to travel with any description of its ambitions.

Blackbird's investment note frames the access challenge around the distribution of specialist talent. That framing explains the appeal of teleoperation: a scarce clinical skill could serve patients beyond a single location. It also places an obligation on the product team to make that skill usable within the receiving hospital's actual capabilities, rather than assuming distance disappears when the connection opens.

The Clinical Network Becomes Part of the Business

Bell brings a clinical background to the company; Sganga brings surgical robotics and a Stanford PhD. Their shared task joins disciplines that a hospital will experience as one service. A physician needs usable images and responsive controls, while a bedside team needs a procedure it can prepare for and support.

Remedy's careers page reflects that breadth through mechanical engineering, development operations, autonomy and technician roles. The product requires hardware, software and clinical work to develop together. The new financing supports that continuing coordination as the company prepares for pivotal trials.

For investors and healthcare operators, the emerging business question is how a specialist network could expand its reach while preserving clear responsibility at each patient location. Remedy's planned trials and prototype partnerships provide places to work through that question. In those hospitals, the people staying with the patient will remain central to what a remote specialist can ultimately do.

DevCuration Data

Healthcare AI funding, last 30 days

DevCuration's funding database tracked 26 Healthcare AI rounds totaling $1.6B in disclosed capital over the past 30 days. Recent deals we covered:

  • Betterness Raises $1M to Expand Miami Wellness NetworksSeed Extension · $1M · Nov 16
  • Knit Health Raises $35M Series A for Clinical AI DeploymentSeries A · $35M · Nov 16
  • Ellipsis Health Acquires Kouper for AI Care NavigationNov 14
  • Kardi Ai Raises Over €5.3M for ECG Monitoring ExpansionSeries A · €5.3M+ · Nov 14
  • Akara Raises $5.5M for Privacy-Preserving Hospital AI$5.5M · Nov 13
All tracked rounds

Frequently Asked Questions

How is N1 designed to support endovascular intervention?

Remedy describes N1 as an investigational robotic platform combining tool control, preoperative simulation and real-time alignment of 3D and 2D images. Its remote package includes connectivity management, audio and video.

What did the Toronto remote procedures demonstrate?

Unity Health Toronto describes remote diagnostic angiograms with the surgeon at St. Joseph’s Health Centre and patients supported by a bedside team at St. Michael’s Hospital. These were diagnostic procedures, distinct from the remote treatments the program aims to develop.

How is the University of California involved with Remedy?

UC Investments joined the Series B as a financial backer. Separately, Remedy plans pivotal clinical trials across the University of California clinical network; neither relationship constitutes FDA approval.

Does working with more than 100 hospitals mean N1 is commercially deployed?

No. Remedy reports those hospital relationships, but does not identify them as a commercial installed base or paying customer count. N1 remains investigational and unavailable for commercial sale.

Which development milestones will the Series B support?

Remedy plans to fund pivotal trials with UC, progress toward FDA approval for neurovascular intervention, prototype partner deployments and further AI and autonomy work. Trial endpoints, enrollment and a regulatory timeline were not disclosed in the announcement.

Back to all articles
Newsletter

Where the Money Moved

The intelligence briefing of the innovation economy. Funding, M&A, debt and fund closes, read as market signal rather than deal announcements.

Subscribe to Where the Money Moved
R

Remedy Robotics

  • San Francisco
WebsiteLinkedIn

Key Executives

  • David Bell
  • CEO and co-founder; Jake Sganga
+1 more (coming soon)

Investors

DCVC
View Career Page

Related Articles

Funding Announcement
Zeromatter Discloses $160M Raised at $1.1B Valuation
Nov 16, 2026
Funding Announcement
Baaz Bikes Board Approves $4.91M Series B Led by BIG Capital
Nov 14, 2026
Funding Announcement
Neurosterix Raises $105M for Schizophrenia Phase 2 Plans
Nov 14, 2026
Funding Announcement
Coreshell Raises $30M Series B for Domestic Battery Scale
Nov 13, 2026
Funding Announcement
Rox Raises $100M Series B for Enterprise Revenue Agents
Nov 13, 2026

More from Jesse Landry

Funding Announcement
Corma Raises $125M Series A for Defensive Cybersecurity
Nov 16, 2026
Funding Announcement
Betterness Raises $1M to Expand Miami Wellness Networks
Nov 16, 2026
Funding Announcement
Focus Financial Partners Agrees to Apollo Strategic Investment
Nov 16, 2026

Trending

Events
AI Infra Summit 6 Examines Who Pays for Inference at Scale
Nov 16, 2026
News
Serve Robotics Opens Physical AI Services to Outside Fleets
Nov 15, 2026
Company Spotlight
Nebuly Company Spotlight: Building Enterprise AI Measurement
Nov 13, 2026
View all posts